A175250 Stock Overview
A biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Icure Pharmaceutical Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,950.00 |
| 52 Week High | ₩3,490.00 |
| 52 Week Low | ₩1,775.00 |
| Beta | 1.1 |
| 11 Month Change | -26.14% |
| 3 Month Change | -18.75% |
| 1 Year Change | -23.23% |
| 33 Year Change | -88.95% |
| 5 Year Change | -76.05% |
| Change since IPO | -90.73% |
Recent News & Updates
Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Sep 04
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?
Aug 28What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You
Jul 21Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
May 31Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?
May 27Recent updates
Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Sep 04Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?
Aug 28What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You
Jul 21Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
May 31Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?
May 27Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio
Mar 07We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt
Dec 25
Shareholder Returns
| A175250 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -10.3% | -0.9% | -4.2% |
| 1Y | -23.2% | -9.2% | -2.7% |
Return vs Industry: A175250 underperformed the KR Personal Products industry which returned -6.5% over the past year.
Return vs Market: A175250 underperformed the KR Market which returned -0.1% over the past year.
Price Volatility
| A175250 volatility | |
|---|---|
| A175250 Average Weekly Movement | 12.0% |
| Personal Products Industry Average Movement | 8.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A175250's share price has been volatile over the past 3 months.
Volatility Over Time: A175250's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 214 | n/a | www.icure.co.kr |
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks.
Icure Pharmaceutical Incorporation Fundamentals Summary
| A175250 fundamental statistics | |
|---|---|
| Market cap | ₩72.87b |
| Earnings (TTM) | -₩23.89b |
| Revenue (TTM) | ₩59.84b |
1.2x
P/S Ratio-3.1x
P/E RatioIs A175250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A175250 income statement (TTM) | |
|---|---|
| Revenue | ₩59.84b |
| Cost of Revenue | ₩54.85b |
| Gross Profit | ₩4.99b |
| Other Expenses | ₩28.88b |
| Earnings | -₩23.89b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -639.22 |
| Gross Margin | 8.34% |
| Net Profit Margin | -39.92% |
| Debt/Equity Ratio | 141.2% |
How did A175250 perform over the long term?
See historical performance and comparison